Format

Send to

Choose Destination
Ann Oncol. 2018 Mar 1;29(3):542-543. doi: 10.1093/annonc/mdy020.

First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma.

Author information

1
Melanoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.
2
Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK.
PMID:
29360923
DOI:
10.1093/annonc/mdy020

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center